Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AMOD vs SLXN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SLXN Captures Overall Composite Edge (24.1 STRONG SELL vs 45.4 HOLD), While AMOD Leads 3–1 on Growth & Valuation Pillars

SLXN Overall Winner 6-Pillar Tally: AMOD 3 – 1 SLXN (2 Tie) Matrix Metrics: AMOD 4 – 2 SLXN

As of Nov 16, 2026, Silexion Therapeutics Corp (SLXN) captures the overall head-to-head institutional edge over Alpha Modus Holdings, Inc. (AMOD) on higher Unified Composite conviction (24.1/100 STRONG SELL vs. 45.4/100 HOLD) after splitting the core matrix 2–4 (led by Balance Sheet & Cash Flow), while AMOD wins 3–1 across the 6-pillar growth and valuation breakdown. AMOD trades at $0.84 (N/M Forward P/E, -127536.2% operating margin) versus SLXN at $1.76 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While AMOD currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. SLXN 24.1/100 STRONG SELL), SLXN captures the overall institutional head-to-head verdict (2–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -127536.2% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: AMOD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.8); meanwhile SLXN is in a Breakdown options structure phase (RSI 66.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AMOD vs SLXN
AMOD NASDAQ
Alpha Modus Holdings, Inc. Class A Common Stock
Patent Owners & Lessors
$0.84
-5.14% 1D
Market Cap $53.3M
TTM Revenue $7,138
Forward P/E N/M
Beta / 30D Vol 51.09β · 120% Vol
Unified Composite Score
45.4 / 100 HOLD
Tech 40.0 Fund 59.0 Flow 50.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -40.6%), weak momentum, RSI 36
RSI-14: 35.8 · SMA20: $1.01 · SMA50: $1.58
SLXN NASDAQ Head-to-Head Winner
Silexion Therapeutics Corp Ordinary Shares
Biological Products, (No Disgnostic Substances)
$1.76
-11.11% 1D
Market Cap $1.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 28.94β · 9931% Vol
Unified Composite Score
24.1 / 100 STRONG SELL
Tech 50.0 Fund 32.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (14.7% over 20 days), RSI 66
RSI-14: 66.0 · SMA20: $0.61 · SMA50: $0.42

6-Pillar Scorecard Institutional Category Breakdown (AMOD 3 – 1 SLXN)

Columns: Metric · AMOD · SLXN
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale AMOD
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $7,138 N/A
Market Cap $53.3M $1.7M
3. Profitability & Quality AMOD
Gross Margin 100.0% N/A
Operating Margin -127536.2% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) 0.0% -897.5%
4. Balance Sheet & Cash Flow SLXN
Cash Generation (TTM) -$4.6M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.2M Net Debt $1.8M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AMOD
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Software - Application Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AMOD (4) vs SLXN (2)
Institutional Metric AMOD SLXN Criterion Row Edge
Market Capitalization
Scale
$53.3M $1.7M Larger Scale AMOD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
-127536.2% 0.0% Higher Margin SLXN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
0.0% -897.5% Higher ROE AMOD
52-Week Range Position
Momentum
11% ($0–$7) 31% ($0–$5) Stronger Trend SLXN
Beta / 30D Volatility
Risk Regime
51.09β · 120% Vol 28.94β · 9931% Vol Lower Realized Risk AMOD
Unified Institutional Score
Composite Signal
45.4 / 100 (HOLD) 24.1 / 100 (STRONG SELL) Higher Composite AMOD
Trailing 12M Revenue (USD)
Operating Scale
$7,138 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.6M ($4.2M Net Debt) N/A ($1.8M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SLXN +1085.34 pp
AMOD: -35.01% · SLXN: +1050.33%
3M Horizon SLXN +401.38 pp
AMOD: -80.53% · SLXN: +320.85%
6M Horizon SLXN +257.71 pp
AMOD: +285.8% · SLXN: +543.51%
1Y Horizon AMOD +25.78 pp
AMOD: -12.9% · SLXN: -38.68%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AMOD vs SLXN. Trailing 12-month operating profitability (AMOD -127536.2% vs SLXN 0.0%) and valuation multiples (AMOD N/M vs SLXN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AMOD ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7,138
Gross Margin100.0%
Op. Margin-127536.2%
ROE / Fwd P/E0.0% · N/M
SLXN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-897.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AMOD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AMOD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SLXN BREAKDOWN
109d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SLXN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AMOD Moat Profile Cyclical / Execution-Driven Positioning
Software - Application Operator
Competes within the Software - Application value chain with $53.3M market capitalization and -127536.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SLXN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AMOD vs SLXN Key Questions & Quantitative Answers

As of Nov 16, 2026, Silexion Therapeutics Corp (SLXN) captures the overall head-to-head institutional edge over Alpha Modus Holdings, Inc. (AMOD) on higher Unified Composite conviction (24.1/100 STRONG SELL vs. 45.4/100 HOLD) after splitting the core matrix 2–4 (led by Balance Sheet & Cash Flow), while AMOD wins 3–1 across the 6-pillar growth and valuation breakdown. AMOD trades at $0.84 (N/M Forward P/E, -127536.2% operating margin) versus SLXN at $1.76 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While AMOD currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. SLXN 24.1/100 STRONG SELL), SLXN captures the overall institutional head-to-head verdict (2–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -127536.2% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: AMOD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.8); meanwhile SLXN is in a Breakdown options structure phase (RSI 66.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AMOD leads the Growth & Scale pillar: AMOD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $7,138 TTM revenue (100.0% gross margin, -127536.2% operating margin), compared with SLXN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AMOD generates $7,138 in USD-normalized revenue versus N/A for SLXN. In operating R&D and SG&A reinvestment, AMOD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SLXN.

AMOD and SLXN trade at balanced relative valuation multiples. AMOD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas SLXN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AMOD (0.0% ROE) versus SLXN (-897.5% ROE) capital efficiency.

In options market volatility and institutional positioning, AMOD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (51.09β · 120% Vol realized risk). By comparison, SLXN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (28.94β · 9931% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.